CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE

The present invention refers to Cx43, preferably in combination with an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK, for use in the treatment of cancer wherein the cancer is characterized by the activation of mitogen-activated pr...

Full description

Saved in:
Bibliographic Details
Main Authors CARPINTERO FERNÁNDEZ, Paula, VARELA EIRÍN, Marta, GUITIÁN CAAMAÑO, Amanda, QUINDÓS VARELA, María, MAYÁN SANTOS, María Dolores, VARELA VÁZQUEZ, Adrián, FONSECA CAPDEVILA, Eduardo, CALLEJA CHUCLA, Teresa
Format Patent
LanguageEnglish
French
German
Published 13.04.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention refers to Cx43, preferably in combination with an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK, for use in the treatment of cancer wherein the cancer is characterized by the activation of mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK.
Bibliography:Application Number: EP20200382883